AR072139A1 - Polimorfos cristalinos de gemcitabina base - Google Patents
Polimorfos cristalinos de gemcitabina baseInfo
- Publication number
- AR072139A1 AR072139A1 ARP090102153A ARP090102153A AR072139A1 AR 072139 A1 AR072139 A1 AR 072139A1 AR P090102153 A ARP090102153 A AR P090102153A AR P090102153 A ARP090102153 A AR P090102153A AR 072139 A1 AR072139 A1 AR 072139A1
- Authority
- AR
- Argentina
- Prior art keywords
- base
- polymorphes
- gemcitabin
- crystal
- ray diffraction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Gemcitabina base de formula (1). Se reivindican las formas A, B, C, D, E y F con los siguientes patrones de difraccion de rayos X en polvo: Forma A: 16,1; 20,7; 6,8; 15,7; 16,7 y 24,3 +- 0,2s 2q; Forma B: 20,8; 23,5; 11,8; 27,8; 30,1; 10,5; 15,8; 22,0; y 33,0 +- 0,2s 2q; Forma C: 14,4; 23,6; 24,4; 12,1; 18,8; 23,0; 29,1; 34,5; y 34,8 +- 0,2s 2q; Forma D: 14,1; 20,7; 10,6; 14,9; 24,4; 27,8; 30,3; 10,1; 17,3; 19,0; 19,7; 22,2; 23,0; 12,1; 18,8; 23,0; y 32,2 +- 0,2s 2q; Forma E: 20,8; 23,5; 10,3; 11,8; 27,5; 30,0; 10,5; 15,8; 22,0; 23,0; 24,7; 28,1; y 33,0 +- 0,2s 2q; Forma F: 20,8; 27,6; 9,4; 11,8; 15,8; 24,3; 30,1; 16,1; 16,8; 22,0; 28,2; y 33,0 +- 0,2s 2q. Reivindicacion 1: Forma cristalina de gemcitabina base, caracterizada por un patron de difraccion de rayos X en polvo con picos a aproximadamente 27,6 y 9,4 +- 0,2s 2q.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13183508P | 2008-06-12 | 2008-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072139A1 true AR072139A1 (es) | 2010-08-11 |
Family
ID=41417138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102153A AR072139A1 (es) | 2008-06-12 | 2009-06-12 | Polimorfos cristalinos de gemcitabina base |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8350023B2 (es) |
| EP (1) | EP2303906B1 (es) |
| JP (1) | JP2011524369A (es) |
| KR (1) | KR101630468B1 (es) |
| CN (1) | CN102216314A (es) |
| AR (1) | AR072139A1 (es) |
| AU (1) | AU2009257344B2 (es) |
| CA (1) | CA2727813A1 (es) |
| NZ (1) | NZ590058A (es) |
| WO (1) | WO2009152421A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103864871B (zh) * | 2014-03-10 | 2016-03-02 | 洪军 | 一种盐酸吉西他滨化合物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526988A (en) * | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| ATE179713T1 (de) * | 1987-08-28 | 1999-05-15 | Lilly Co Eli | Verfahren zur selektiven isolierung von beta-2'- desoxy-2'2'-difluorocytidin oder seiner salze |
| US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US7919119B2 (en) * | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| WO2006071090A1 (en) * | 2004-12-30 | 2006-07-06 | Hanmi Pharm. Co., Ltd. | Method for the preparation of 2'-deoxy-2',2'-difluorocytidine |
| WO2006070985A1 (en) * | 2004-12-30 | 2006-07-06 | Hanmi Pharm. Co., Ltd. | METHOD FOR THE PREPARATION OF 2#-DEOXY-2#,2#-DIFLUOROCYTIDINE |
| FR2889437B1 (fr) | 2005-08-02 | 2008-04-18 | Euro Sa | Implant rachidien a moyen de blocage pivotant pour une tige de liaison |
| MX2009000198A (es) * | 2006-06-21 | 2009-01-22 | Lilly Co Eli | Formas cristalinas de profarmaco amida de gemcitabina, composiciones y usos del mismo. |
| CN100475832C (zh) * | 2007-05-31 | 2009-04-08 | 南京卡文迪许生物工程技术有限公司 | 一种新颖的高立体选择性合成吉西他滨工艺及中间体 |
-
2009
- 2009-06-12 CA CA2727813A patent/CA2727813A1/en not_active Abandoned
- 2009-06-12 US US12/483,375 patent/US8350023B2/en active Active
- 2009-06-12 NZ NZ590058A patent/NZ590058A/xx not_active IP Right Cessation
- 2009-06-12 CN CN2009801312900A patent/CN102216314A/zh active Pending
- 2009-06-12 WO PCT/US2009/047190 patent/WO2009152421A1/en active Application Filing
- 2009-06-12 EP EP09763709.4A patent/EP2303906B1/en active Active
- 2009-06-12 AR ARP090102153A patent/AR072139A1/es unknown
- 2009-06-12 JP JP2011513726A patent/JP2011524369A/ja active Pending
- 2009-06-12 AU AU2009257344A patent/AU2009257344B2/en active Active
- 2009-06-12 KR KR1020117000722A patent/KR101630468B1/ko active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US8350023B2 (en) | 2013-01-08 |
| JP2011524369A (ja) | 2011-09-01 |
| CN102216314A (zh) | 2011-10-12 |
| KR101630468B1 (ko) | 2016-06-14 |
| AU2009257344A2 (en) | 2011-04-21 |
| EP2303906A4 (en) | 2014-12-03 |
| EP2303906B1 (en) | 2016-06-08 |
| AU2009257344A1 (en) | 2009-12-17 |
| US20090326214A1 (en) | 2009-12-31 |
| AU2009257344B2 (en) | 2014-03-20 |
| WO2009152421A1 (en) | 2009-12-17 |
| KR20110036735A (ko) | 2011-04-08 |
| CA2727813A1 (en) | 2009-12-17 |
| EP2303906A1 (en) | 2011-04-06 |
| NZ590058A (en) | 2012-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063347A1 (es) | Formas cristalinas de docetaxel y proceso para su preparacion | |
| ECSP109922A (es) | Compuestos de pirazol y su uso como inhibidores raf | |
| NI200800294A (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen. | |
| AR072777A1 (es) | Formas solidas de clorhidrato de bendamustina | |
| FR2889597B1 (fr) | Plaque texturee a motifs asymetriques | |
| DOP2009000039A (es) | COMPUESTOS DE PIRIDO (2,3-D) PIRIMIDINONA Y SU USO COMO INHIBIDORES DE P13-Ka | |
| BRPI0514372A (pt) | inibidores de tiazol de frutose 1, 6-bisfosfatase | |
| CR20110370A (es) | Derivados de sulfonamida | |
| ECSP099817A (es) | Procesos para la preparacion de pirazoles | |
| BRPI0608886B8 (pt) | derivados de n-sulfonilpirróis e seus usos | |
| CR10157A (es) | Compuestos químicos | |
| PE20070214A1 (es) | Formas cristalinas de la 4-metil-n-[3-(4-metil-imidazo-1-lil)-5-trifluoreometil-fenil]-3-(4-piridi-3-nil-pirimidi-2-nilamino)-benzamida | |
| EA200801959A1 (ru) | Высокоразветвленный полипропилен | |
| ATE553134T1 (de) | Strahlungsbeugungsfarbmittel | |
| UY30639A1 (es) | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones | |
| BRPI0817131A2 (pt) | gerenciamento de interferência empregando reutilização de tempo fracional | |
| CY1112467T1 (el) | Παραγωγα 1-θειο-d-γλυκιτολης | |
| DK1859793T3 (da) | Hidtil ukendt kombinationsanvendelse af en sulfonamidforbindelse i behandlingen af cancer | |
| DE502006000995D1 (de) | Generator mit hoher phasenordnung | |
| ATE487691T1 (de) | Acetylenderivate | |
| ECSP11011054A (es) | Péptidos antivirales terapéuticos | |
| FI20055630A (fi) | Kasvonaamio | |
| NL1028723A1 (nl) | Differentiele interferometers welke gewenste bundelpatronen verschaffen. | |
| DK1966217T3 (da) | Nye, acyklisk substituerede furopyrimidin-derivater, anvendelsen heraf til behandling af kardiovaskulære sygedomme | |
| UY29804A1 (es) | Quinolinas de alquilnitrilo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |